Coave Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $33.3M

  • Investors
  • 19

Coave Therapeutics General Information

Description

Developer of genetic medicine technologies intended to address neurodegenerative diseases through targeted therapies. The company's platform is useful for delivering low doses of therapeutic genes like GBA1 and TFEB directly to the central nervous system, enhancing autophagy and lysosomal function, enabling researchers and healthcare providers to develop effective treatments for conditions such as ALS and other related disorders while improving patient outcomes and quality of life.

Contact Information

Website
www.coavetx.com
Formerly Known As
Horama
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 63bis avenue Ledru Rolin
  • 75012 Paris
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 63bis avenue Ledru Rolin
  • 75012 Paris
  • France
+33 01

Coave Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Coave Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A) 09-Jan-2025 $33.3M Completed Pre-Clinical Trials
8. Accelerator/Incubator Completed Pre-Clinical Trials
7. Accelerator/Incubator Completed Pre-Clinical Trials
6. Later Stage VC 15-Dec-2022 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 02-Dec-2021 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 18-Sep-2018 Completed Startup
3. Early Stage VC (Series A) 08-Jul-2016 Completed Startup
2. Grant 02-Jul-2015 $167K $905K Completed Startup
1. Early Stage VC (Series A) 03-Mar-2015 $905K $905K Completed Startup
To view Coave Therapeutics’s complete valuation and funding history, request access »

Coave Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B Shares
B Shares
ABSA B
ABSA A 8,218 $3.131646 $1252.66 $1252.66 $1252.66 12.07%
Ordinary 666 $3.131646 $1252.66 $1252.66 $1252.66 0.98%
To view Coave Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Coave Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of genetic medicine technologies intended to address neurodegenerative diseases through targeted therapies. Th
Drug Discovery
Paris, France
34 As of 2023

Ecublens, Switzerland
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Coave Therapeutics Competitors (40)

One of Coave Therapeutics’s 40 competitors is Anokion, a Venture Capital-Backed company based in Ecublens, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anokion Venture Capital-Backed Ecublens, Switzerland
Cerevance Venture Capital-Backed Boston, MA
Verge Genomics Venture Capital-Backed South San Francisco, CA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Neurogene Formerly VC-backed New York, NY
You’re viewing 5 of 40 competitors. Get the full list »

Coave Therapeutics Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Coave Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220380803-A1 Lactam-modified adeno-associated virus vectors Pending 12-May-2021
AU-2021374832-A1 Lactam-modified adeno-associated virus vectors Pending 06-Nov-2020
AU-2021374832-A9 Lactam-modified adeno-associated virus vectors Pending 06-Nov-2020
CA-3196597-A1 Lactam-modified adeno-associated virus vectors Pending 06-Nov-2020
EP-4240837-A1 Lactam-modified adeno-associated virus vectors Pending 06-Nov-2020 C12N15/86
To view Coave Therapeutics’s complete patent history, request access »

Coave Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Coave Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Novo Holdings Corporate Venture Capital Minority
The Invus Group PE/Buyout Minority
UI Investissement PE/Buyout Minority
EureKare VC-Backed Company Minority
Seroba Life Sciences Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Coave Therapeutics Acquisitions (1)

Coave Therapeutics’s most recent deal was a Merger/Acquisition with Aloop Therapeutics. The deal was made on 02-Jun-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aloop Therapeutics 02-Jun-2025 Merger/Acquisition Biotechnology
To view Coave Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Coave Therapeutics FAQs

  • When was Coave Therapeutics founded?

    Coave Therapeutics was founded in 2014.

  • Where is Coave Therapeutics headquartered?

    Coave Therapeutics is headquartered in Paris, France.

  • What is the size of Coave Therapeutics?

    Coave Therapeutics has 34 total employees.

  • What industry is Coave Therapeutics in?

    Coave Therapeutics’s primary industry is Drug Discovery.

  • Is Coave Therapeutics a private or public company?

    Coave Therapeutics is a Private company.

  • What is Coave Therapeutics’s current revenue?

    The current revenue for Coave Therapeutics is .

  • How much funding has Coave Therapeutics raised over time?

    Coave Therapeutics has raised $80.8M.

  • Who are Coave Therapeutics’s investors?

    Novo Holdings, The Invus Group, UI Investissement, EureKare, and Seroba Life Sciences are 5 of 19 investors who have invested in Coave Therapeutics.

  • Who are Coave Therapeutics’s competitors?

    Anokion, Cerevance, Verge Genomics, ONL Therapeutics, and Neurogene are some of the 40 competitors of Coave Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »